AZN Related Insiders' Blog
-
Amarin (AMRN) Higher as Teva (TEVA) Said to be Waiting in the Wings for a Takeover
-
Amarin (AMRN) Is 'In Play'
-
"Patent Cliff" Takes Toll on Drug Sales
-
Amarin (AMRN) Investors Look Beyond NCE Status and to a Buyout
-
Medivation (MDVN) Ripe for the Picking on Expected Enzalutamide Approval
-
Amylin (AMLN) Shares Pop on New M&A Chatter (BMY) (AZN)
-
Targacept (TRGT) Can Fail and Yet Still Win for Investors - Barron's
-
AstraZeneca (AZN) Lower, Loses Certain CRESTOR Patent Decision
-
Targacept (TRGT) Slammed Following RENAISSANCE Phase 3 Endpoint Miss
-
AstraZeneca (AZN) Slumps as FDA Requests Additional PLATO Data for BRILINTA
-
Soros' Moves Lower in Telecom, Major Retailers; Becomes Bullish on the U.S. Dollar (T, S, UUP, WMT, SIRI, More...)
-
Lampert's RBS Partners Reduces Holdings, Gets Financial Exposure with Genworth (GNW)
-
Drug Makers Higher On Health Care Reform (PFE, MRK, TEVA, more...)
-
Jim Chanos Steps Up Health-Care Shorts (AZN, SI)
-
Amylin (AMLN) Tumbles as Competitor to Byetta, Novo Nordisk's liraglutide, Does Not Receive FDA Recommendation
-
Positive Barron's Article Can't Help Abbott Labs (ABT) Stock Today
-
Could Icahn Target Biogen Idec (BIIB) Next?
Back to AZN Stock Lookup
